Answers are grounded in this paper and cite their sources.
Basal cell carcinoma (BCC) is the most common type of cancer, yet mouse models of BCC are limited. Existing BCC mouse models such as the Ptch1 +/- - K14 - CreER T2 p53 fl/fl -tumor (GEM-BCC) model rely on genetic engineering. Spontaneous tumor models are essential for studying carcinogenesis, however the heterogeneous growth of multiple tumors requires large group sizes, making them challenging to implement in early-stage drug development. This study describes the establishment of an immunocompetent transplantable BCC (Tp-BCC) mouse model suitable for preclinical treatment evaluation. By in vivo passaging GEM-BCC tumor cells, we established a subcutaneous Tp-BCC model. We compared microstructural features, tumor microenvironment and transcriptional profile of the Tp-BCC model with its parental GEM-BCC model using histology, flow cytometry and RNA sequencing. Tp-BCC tumors displayed synchronized growth and shortened time until formation compared to GEM-BCC tumors. Tp-BCC tumors showed micro-nodular histological structure, maintained K14 expression and had a low immune infiltration similar to the GEM-BCC tumors. Hedgehog signaling pathway-related genes were similarly expressed except for Igf2. The transcriptional profile of Tp-BCC tumors was more homogenous than the GEM-BCC tumors. This study demonstrates that the Tp-BCC model retains key features of the GEM-BCC model and provides a complementary, immunocompetent, high-throughput platform for early-stage BCC therapeutic development.
No takes yet. Share an insight, caveat, or question.
Wiinberg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: